Human opiorphin: The lack of physiological dependence, tolerance to antinociceptive effects and abuse liability in laboratory mice

Behavioural Brain Research

Volumn 213, Issue 1, 2010, Pages 88-93

  Popik, Piotr ^a   Kamysz, Elzbieta ^b   Kreczko, Joanna ^b   Wróbel, Małgorzata ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Animal model; Antidepressant effect; Antinociception; Conditioned reward; Dependence; Opiorphin; Tolerance

Indexed keywords

ANTINOCICEPTIVE AGENT; DESIPRAMINE; MORPHINE; NALOXONE; OPIORPHIN; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG TOLERANCE; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; REPEATED DRUG DOSE;

ANALGESICS, OPIOID; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CONDITIONING, CLASSICAL; DEPRESSION; HUMANS; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MORPHINE; NALOXONE; NEUROPSYCHOLOGICAL TESTS; OLIGOPEPTIDES; PAIN; RECEPTORS, OPIOID; SALIVARY PROTEINS AND PEPTIDES; SPACE PERCEPTION; SUBSTANCE-RELATED DISORDERS;

EID: 77953361591     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.04.045     Document Type: Article

References (39)

1. Baamonde A., Dauge V., Ruiz-Gayo M., Fulga I.G., Turcaud S., Fournie-Zaluski M.C., et al. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol 1992, 216:157-166.
2. Barlos K., Chatzi O., Gatos D., Stavropoulos G. 2-Chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage. Int J Pept Protein Res 1991, 37:513-520.
3. Blum K, Briggs AH, Wallace JE. Enkephalinase and endorphinase inhibitors as anti-craving compositions. US Patent 4,761,429; 1988.
4. Broom D.C., Jutkiewicz E.M., Folk J.E., Traynor J.R., Rice K.C., Woods J.H. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 2002, 26:744-755.
5. Chan W.C., White P.D. Fmoc solid phase peptide synthesis. A practical approach 2000, Oxford University Press, Oxford.
6. Cordonnier L., Sanchez M., Roques B.P., Noble F. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 2005, 135:1-10.
7. Davies K.P., Tar M., Rougeot C., Melman A. Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. BJU Int 2007, 99:431-435.
8. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W.D., Simonin F., et al. Mice deficient for delta- and gamma-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000, 25:195-200.
9. Fournie-Zaluski M.C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., et al. "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem 1992, 35:2473-2481.
10. Hebert M.A., Ardid D., Henrie J.A., Tamashiro K., Blanchard D.C., Blanchard R.J. Amygdala lesions produce analgesia in a novel, ethologically relevant acute pain test. Physiol Behav 1999, 67:99-105.
11. Jaffe J.H. Drug addiction and drug abuse. Goodman and Gilman's the pharmacological basis of therapeutics 1985, 532-588. Macmillan Publishing Company, New York. 17th ed. A.G. Gilman, L.S. Goodman, T.W. Rall, F. Murad (Eds.).
12. Jutkiewicz E.M. The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 2006, 6:162-169.
13. Jutkiewicz E.M. RB101-mediated protection of endogenous opioids: potential therapeutic utility?. CNS Drug Rev 2007, 13:192-205.
14. Jutkiewicz E.M., Torregrossa M.M., Sobczyk-Kojiro K., Mosberg H.I., Folk J.E., Rice K.C., et al. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur J Pharmacol 2006, 531:151-159.
15. Kastin A.J., Scollan E.L., Ehrensing R.H., Schally A.V., Coy D.H. Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 1978, 9:515-519.
16. Katz R.J., Gormezano G. A rapid and inexpensive technique for assessing the reinforcing effects of opiate drugs. Pharmacol Biochem Behav 1979, 11:231-233.
17. Kos T., Popik P. A comparison of the predictive therapeutic and undesired side-effects of NMDA receptor antagonist, memantine in mice. Behav Pharmacol 2005, 16:155-161.
18. Layer R.T., Skolnick P., Bertha C.M., Kuehne M.E., Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur J Pharmacol 1996, 309:159-165.
19. Messaoudi M., Desor D., Nejdi A., Rougeot C. The endogenous androgen-regulated sialorphin modulates male rat sexual behavior. Horm Behav 2004, 46:684-691.
20. Noble F., Fournie-Zaluski M.C., Roques B.P. Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice. Eur J Pharmacol 1993, 230:139-149.
21. Noble F., Soleilhac J.M., Soroca-Lucas E., Turcaud S., Fournie-Zaluski M.C., Roques B.P. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 1992, 261:181-190.
22. Noble F., Turcaud S., Fournie-Zaluski M.C., Roques B.P. Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. Eur J Pharmacol 1992, 223:83-89.
23. Paronis C.A., Holtzman S.G. Increased analgesic potency of mu agonists after continuous naloxone infusion in rats. J Pharmacol Exp Ther 1991, 259:582-589.
24. Phillips A.G., LePiane F.G. Reward produced by microinjection of (D-Ala), Met-enkephalinamide into the ventral tegmental area. Behav Brain Res 1982, 5:225-229.
25. Popik P., Kos T., Sowa-Kucma M., Nowak G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology 2008, 198:421-430.
26. Popik P., Wrobel M., Rygula R., Bisaga A., Bespalov A.Y. Effects of memantine, an NMDA receptor antagonist on place preference conditioned with drug and non-drug reinforcers in mice. Behav Pharmacol 2003, 14:237-244.
27. Roques B.P., Noble F., Dauge V., Fournie-Zaluski M.C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993, 45:87-146.
28. Rougeot C., Messaoudi M., Hermitte V., Rigault A.G., Blisnick T., Dugave C., et al. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. Proc Natl Acad Sci USA 2003, 100:8549-8554.
29. Rougeot C, Rougeon F. Treatment of mood disorders by administration of SMR1. US Patent 7,423,020 B2; 2008.
30. Tejedor-Real P., Mico J.A., Smadja C., Maldonado R., Roques B.P., Gilbert-Rahola J. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 1998, 354:1-7.
31. Thanawala V., Kadam V.J., Ghosh R. Enkephalinase inhibitors: potential agents for the management of pain. Curr Drug Targets 2008, 9:887-894.
32. Tian X.Z., Chen J., Xiong W., He T., Chen Q. Effects and underlying mechanisms of human opiorphin on colonic motility and nociception in mice. Peptides 2009, 30:1348-1354.
33. Valverde O., Blommaert A.G., Fournie-Zaluski M.C., Roques B.P., Maldonado R. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Eur J Pharmacol 1995, 286:79-93.
34. Van Ree J.M., Niesink R.J., Van Wolfswinkel L., Ramsey N.F., Kornet M.M., Van Furth W.R., et al. Endogenous opioids and reward. Eur J Pharmacol 2000, 405:89-101.
35. VanRee J.M., Gerrits M.A.F.M., Vanderschuren L.J.M.J. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol Rev 1999, 51:341-396.
36. Vergura R., Valenti E., Hebbes C.P., Gavioli E.C., Spagnolo B., Mcdonald J., et al. Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides 2006, 27:3322-3330.
37. Willner P. The validity of animal models of depression. Psychopharmacology 1984, 83:1-16.
38. Wisner A., Dufour E., Messaoudi M., Nejdi A., Marcel A., Ungeheuer M.N., et al. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA 2006, 103:17979-17984.
39. Yamamoto Y., Ono H., Ueda A., Shimamura M., Nishimura K., Hazato T. Spinorphin as an endogenous inhibitor of enkephalin-degrading enzymes: roles in pain and inflammation. Curr Protein Pept Sci 2002, 3:587-599.